Roche to Acquire 89bio in $3.5 Billion Deal Bolstering its MASH Pipeline
The definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read more
Metabolic
Sanofi Secures China Rights to RNAi Candidate for Hypertriglyceridemia from Arrowhead
In a major regional licensing agreement, Sanofi has entered into an asset purchase deal with Visirna Therapeutics, a majority-owned subsidiary
Read more
Lexicon Secures $1 Billion Deal with Novo Nordisk for Obesity Candidate
Lexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read more
Variant Bio Partners with Novo Nordisk to Discover Novel Targets for Metabolic Disease
Variant Bio, a leading genomics-driven drug discovery company, announced today it is entering a new, multi-year research collaboration with pharmaceutical
Read more
insitro and Lilly Forge Partnerships to Advance AI-Powered siRNA Drugs for Metabolic Diseases
Insitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read more
Ironwood to Acquire VectivBio for $1B in Late-stage Digestive Therapy Deal
The $1 billion acquisition deal is set to advance Ironwood’s vision of becoming the leading gastrointestinal healthcare company. Ironwood Pharmaceuticals,
Read more
Sanofi Expands Diabetes Portfolio with $2.9 Billion Deal for Provention Bio
TZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read more
Abbott receives CE Mark for smallest real-time Glucose Monitoring Sensor
Abbott, a global leader in continuous glucose monitoring (CGM) technology, announced it has been awarded CE Mark (Conformité Européenne) for
Read more